Despite a greater prevalence than HIV/AIDS or any cancer, chronic viral hepatitis has a relatively low profile, according to the organizers of World Hepatitis Day. An instance of this came recently when the World Health Organization dropped the issue from its latest World Health Assembly gathering in Geneva, Switzerland, in order to focus on the immediate problems posed by the swine influenza crisis (Marketletter May 25).
The World Hepatitis Alliance is calling for more international efforts to be made to prevent and treat hepatitis B and C, which affect one in 12 people worldwide, with about one million fatalities per year. On May 19, a campaign titled "am I Number 12?" was launched to coincide with World Hepatitis Day.
The best way to prevent hepatitis B is immunization, which has been an option since 1982, which the WHA states is "approximately 95% effective." Unfortunately, many of the countries most affected by the disease do not have comprehensive vaccination programs for hepatitis B, especially in the Indian sub-continent and sub-Saharan Africa.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze